SA
PLX icon

Sanctuary Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Sanctuary Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-37,100
Closed -$62.7K – 2469
2024
Q3 		$62.7K Buy
+37,100
New +$39K ﹤0.01% 2336

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Sanctuary Advisors's PLX Position: Q4 2024 in Review

Sanctuary Advisors sold out of Protalix BioTherapeutics (PLX) in Q4 2024, closing a stake of 37,100 shares — an estimated $62.7K sold.

Sanctuary Advisors first reported a position in PLX in Q3 2024 and held it in 1 quarter. The position peaked at $62.7K in Q3 2024. 45 funds tracked by Wall St. Rank hold PLX as of Q4 2024.

  • Sanctuary Advisors reported no remaining Protalix BioTherapeutics position as of Q4 2024 after selling out during the quarter.
  • Sanctuary Advisors sold 37,100 Protalix BioTherapeutics shares in Q4 2024, an estimated $62.7K.
  • Sanctuary Advisors first reported a position in Protalix BioTherapeutics in Q3 2024 and held it in 1 quarter.
  • Sanctuary Advisors's Protalix BioTherapeutics position peaked at $62.7K in Q3 2024.
  • 45 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2024.

Based on Sanctuary Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.